Phase 2, AZD5423 BY ASTRAZENECA FOR COPD

New Drug Approvals

AZD5423

The compound is now in a Phase II study in patients with COPD, where its efficacy and safety are being measured against that of a typical steroid or a placebo

A phase II drug structure by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular the chronic obstructive pulmonary disease.[1][2][3][4]

 

View original post

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s